KLRS
Kalaris Therapeutics, Inc.
NASDAQ: KLRS · HEALTHCARE · BIOTECHNOLOGY
$5.52
+0.18% today
Updated 2026-04-30
Market cap
$138.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.85
Dividend yield
—
52W range
$2 – $12
Volume
0.1M
Kalaris Therapeutics, Inc. (KLRS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14M | $165000.00 | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -85.5% | -100.0% | — | — | — | — | — |
| Cost of revenue | — | — | $73000.00 | $1.12M | — | — | — | $13000.00 |
| Gross profit | — | — | $-73000.00 | $-1.12M | — | — | — | $-13000.00 |
| Gross margin | 0.0% | 0.0% | — | — | — | — | — | — |
| R&D | $1.70M | $16.23M | $49.59M | $119.62M | $11.76M | $11.71M | $12.34M | $30.75M |
| SG&A | — | — | — | — | $2.24M | $1.76M | $6.69M | $15.40M |
| Operating income | $-3.60M | $-26.70M | $-71.31M | $-169.82M | $-14.01M | $-13.46M | $-55.26M | $-46.15M |
| Operating margin | -316.8% | -16182.4% | — | — | — | — | — | — |
| EBITDA | $-2.43M | $-23.82M | $-69.71M | $-169.84M | $-15.25M | $-14.01M | $-58.77M | $-46.14M |
| EBITDA margin | -214.1% | -14436.4% | — | — | — | — | — | — |
| EBIT | — | $-23.84M | $-69.78M | $-170.96M | $-14.01M | $-13.46M | — | $-46.15M |
| Interest expense | — | — | — | — | $235000.00 | $687000.00 | $2.70M | $1.44M |
| Income tax | — | — | — | $1.01M | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | -0.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.43M | $-23.84M | $-69.78M | $-171.96M | $-15.48M | $-14.70M | $-58.77M | $-43.44M |
| Net income growth (YoY) | — | -881.0% | -192.7% | -146.4% | +91.0% | +5.1% | -299.8% | +26.1% |
| Profit margin | -214.1% | -14447.9% | — | — | — | — | — | — |